Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Cedars-Sinai Women's Heart Center Launches Advanced Preventive Women's Clinic For Women With Menopause Symptoms Who Are At Risk For Heart Disease
Women who are at risk for heart disease and who are also experiencing menopause symptoms now have an added re - a highly specialized clinic in the Division of Cardiology at the Cedars-Sinai Heart Institute. The Advanced Preventive Women"s Clinic at the Women"s Heart Center recently opened and is offering comprehensive cardiac risk assessments designed specifically for women who are in menopause. The clinic also offers menopausal patients state-of-the-art screenings, as well as personalized medicine therapies and counseling, including high-risk hormone counseling.
generic viagra online
Lawmakers Spar Over Health Reform
As the Senate Finance Committee prepares to unveil a health overhaul proposal this week, key players have been weighing in on aspects of potential legislation. Drugshop to buy zoloft online and other pills.
News of the day
Volt's Dr. McCaffrey To Present Genetic Algorithm Study Results At COMPSAC 2009
Dr. James McCaffrey, Associate Vice President of Volt Technical Res, a staffing business of Volt Information Sciences, Inc. will present new research at the 33rd Annual IEEE Computer Software and Applications Conference (COMPSAC 2009), July 20-24, 2009 in Seattle. McCaffrey will present "Generation of Pairwise Test Sets Using a Genetic Algorithm."
Oncology

Pharming Receives Agreement On Paediatric Investigation Plan For Rhucin(R) From The EMEA Paediatric Committee

Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that the Paediatric Committee (PDCO) of the European Medicines Agency (EMEA) has adopted an opinion agreeing the paediatric investigation plan (PIP) for Rhucin® (recombinant human C1 inhibitor) in the therapeutic area of immunology-rheumatology transplantation. "Agreement of the PIP represents a key milestone in Pharming"s regulatory plans for the September 2009 submission of the Rhucin marketing authorisation application," said Dr. Bruno Giannetti, COO of Pharming. According to the EC Regulation 1901/2006 of 12 December 2006, pharmaceutical companies that submit an application for a marketing authorisation for a medicinal product (MAA) in the EU, have to include an approved PIP as part of the regulatory submission. Pharming Group NV


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009